Market News
Stay updated with the latest market trends, earnings, and economic indicators.
AstraZeneca Pharma India closes trading window from June 16, 2026 - scanx.trade
AstraZeneca Pharma India closes trading window from June 16, 2026scanx.trade
AstraZeneca Pharma India gets CDSCO nod for expanded use of breast cancer drug Enhertu
The approval expands the eligible patient population for the therapy in India and allows AstraZeneca to market the drug for the additional indication, subject to any other required statutory clearances.
AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancer
AstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its import, sale, and distribution for an additional use. The drug will now be available as a first-line treatment for certain types of advanced breast cancer. This development expands treatment options for oncologists and patients facing HER2-positive breast cancer.
AstraZeneca Pharma shares slip 6% on posting 23% fall in Q4 profit YoY
In the March quarter, AstraZeneca Pharma reported a 23 per cent year-on-year (Y-o-Y) decline in consolidated net profit to ₹44.9 crore, from ₹58.25 crore a year ago
AstraZeneca Pharma Q4 Results: Profit Down 23%, Revenue Rises
For the entire FY26, AstraZeneca's net profit jumped 62% to Rs 187.52 crore.
AstraZeneca Pharma India Q4 profit drops 23% despite strong revenue growth
Oncology, biopharma growth drive FY26 performance; board recommends ₹36/share dividend
Q4 Results Today: ONGC, IRCTC, Siemens, Senco Gold Among 280+ Firms To Declare Earnings On May 26
Redtape, Gujarat Fluorochemicals, AstraZeneca Pharma India & Bajali Telefilms are among the other companies to declare their Q4FY26 results on May 26.
Stocks to Watch Today: Swiggy, Enviro Infra, Advait Energy, AstraZeneca, Torrent Pharma, Laxmi Organic,... - Moneycontrol.com
Stocks to Watch Today: Swiggy, Enviro Infra, Advait Energy, AstraZeneca, Torrent Pharma, Laxmi Organic,...Moneycontrol.com
AstraZeneca Pharma gets CDSCO nod to import leukaemia drug Calquence 100 mg tablets
Following the approval, acalabrutinib tablets 100 mg in combination with venetoclax with or without obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). Shares of Astrazeneca Pharma India Ltd ended at ₹8,291.50, up by ₹235.70, or 2.93%, on the BSE today, April 10.
AstraZeneca India plans to sell 64-acre Bengaluru site for Rs 3,400 crore
The land parcel, expected to fetch about ₹3,400 crore for AstraZeneca Pharma India, has drawn interest from developers including the Sattva Group, Aurobindo Pharma and RMZ. The company is looking to sell it as part of a broader land monetisation strategy.
AstraZeneca Pharma India gets approval for Imfinzi in liver cancer treatment
AstraZeneca Pharma India got CDSCO approval to market Durvalumab for unresectable hepatocellular carcinoma, expanding its oncology portfolio. Shares closed 0.33% higher at ₹8,403.
AstraZeneca falls 7% as Q4 net profit declines 23%; here's a trading strategy for the pharma stock
An analyst said the decline in the stock was largely due to profit booking and did not indicate a reversal in the broader trend.